Surge in the prevalence of chronic diseases and increase in proteomics research have boosted the growth of the global protein therapeutics market. However, high production costs required for developing and manufacturing protein-based therapeutics hinder the market growth. On the contrary, surge in healthcare expenditure and increase in geriatric populations would open new opportunities for the market players in the future.
Growth of the global protein therapeutics market is attributed to increase in prevalence of chronic diseases, surge in development of protein-based therapies, and various strategies adopted by key players of the market. Moreover, increase in healthcare expenditure and approval of new products are expected to further drive the market growth during the forecast period.
Download Sample Report-ย https://www.alliedmarketresearch.com/request-sample/60
Therapeutic proteins are an important class of drugs, which serve patients in need of novel therapies. Approved recombinant protein therapeutics are developed to treat a wide array of clinical indications, including cancers, genetic disorders, infectious diseases, and metabolic disorders.
The major factors that drive the growth of theย global protein therapeutics marketย include introduction & application of new plasma-derived therapies, surge in prevalence of chronic & life-threatening diseases, and rise in awareness among populace regarding the high efficiency of protein therapeutics. However, high cost of protein therapies and complex reimbursement scenario impede the market growth. Conversely, increase in novel indications for known protein therapeutics and untapped emerging markets are anticipated to provide lucrative opportunities for the manufacturers in this industry.
(๐๐ง ๐ญ๐จ๐๐๐ฒโ๐ฌ ๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐ฆ๐๐ซ๐ค๐๐ญ, ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐ข๐ฌ ๐ ๐๐ซ๐ข๐ญ๐ข๐๐๐ฅ ๐ฌ๐ญ๐๐ฉ ๐ข๐ง ๐ข๐๐๐ง๐ญ๐ข๐๐ฒ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐จ๐ซ๐ซ๐๐๐ญ ๐ญ๐๐ซ๐ ๐๐ญ ๐๐จ๐ง๐ฌ๐ฎ๐ฆ๐๐ซ๐ฌ ๐๐ง๐ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐ข๐ง๐ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ฌ๐๐ ๐ฌ๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐๐ข๐ซ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ง๐๐๐๐ฌ. ๐๐ก๐ข๐ฅ๐ ๐๐จ๐ซ๐ฆ๐ฎ๐ฅ๐๐ญ๐ข๐ง๐ ๐ญ๐ก๐๐ฌ๐ ๐ฌ๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ, ๐๐ฏ๐๐ซ๐ฒ ๐๐๐๐๐ญ ๐๐ง๐ ๐ฌ๐ฉ๐๐๐ข๐๐ข๐ ๐ฉ๐ซ๐จ๐๐ฅ๐๐ฆ ๐ฉ๐ซ๐๐ฌ๐๐ง๐ญ๐๐ ๐๐ฒ ๐ญ๐ก๐ ๐ฉ๐๐ซ๐ญ๐ข๐๐ฎ๐ฅ๐๐ซ ๐ฌ๐๐๐ญ๐จ๐ซ ๐ข๐ฌ ๐ญ๐ก๐จ๐ซ๐จ๐ฎ๐ ๐ก๐ฅ๐ฒ ๐๐จ๐ง๐ฌ๐ข๐๐๐ซ๐๐. ๐๐ญ ๐๐ฅ๐ฌ๐จ ๐๐จ๐ง๐ฌ๐ข๐๐๐ซ๐ฌ ๐ง๐ฎ๐ฆ๐๐ซ๐จ๐ฎ๐ฌ ๐ ๐จ๐ฏ๐๐ซ๐ง๐ฆ๐๐ง๐ญ ๐ซ๐๐๐จ๐ซ๐ฆ๐ฌ, ๐ญ๐ก๐ ๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐ง๐ฏ๐ข๐ซ๐จ๐ง๐ฆ๐๐ง๐ญ, ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐๐ซ ๐๐๐ก๐๐ฏ๐ข๐จ๐ฎ๐ซ, ๐๐ฎ๐ซ๐ซ๐๐ง๐ญ ๐๐ง๐ ๐๐ฎ๐ญ๐ฎ๐ซ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ฌ๐ญ๐ซ๐๐ญ๐๐ ๐ข๐๐ฌ, ๐๐ง๐ ๐ซ๐๐ฉ๐ข๐๐ฅ๐ฒ ๐๐ก๐๐ง๐ ๐ข๐ง๐ ๐ญ๐๐๐ก๐ง๐ข๐๐๐ฅ ๐๐ซ๐๐๐ค๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก๐ฌ. ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐๐ข๐๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐จ๐ซ๐ฆ๐ฎ๐ฅ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ฉ๐ฅ๐๐ง๐ฌ ๐๐ง๐ ๐ฉ๐จ๐ฅ๐ข๐๐ข๐๐ฌ.)
Covid-19 scenario:
- The Covid-19 pandemic had a positive impact on the growth of protein therapeutics due to surge in chronic diseases and increase in demand for therapeutic drugs.
- The number of clinics and hospitals across the globe increased during the pandemic, which supplemented the demand for protein therapeutics.
- However, the prolonged lockdown and disruptions of manufacturing and transportation of healthcare essentials hinder the market.
Get detailed COVID-19 impact analysis on the Protein Therapeutics Market-ย
https://www.alliedmarketresearch.com/request-for-customization/60?reqfor=covid
High development & manufacturing cost, high treatment costs per patient, stringent government regulations, and complex reimbursement scenario are expected to impede the protein therapeutics market growth. Conversely, high market potential in the untapped emerging economies, rise in various product launches, partnerships, and collaborations among governments & key players, and development of pipeline products are expected to provide many opportunities for the market growth during the forecast period.
By product, the market is segmented into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle stimulating hormone. The monoclonal antibodies segment generated maximum revenue in 2020, accounting for $136.9 billion. The fusion protein segment is expected to witness highest CAGR of 9.5% during the forecast period.
North Americaย held the largest share
By region, the market acrossย North Americaย dominated the market in 2020, holding nearly half of the market, due to increase in chronic diseases, rapid adoption of advanced technologies, and presence of key players in the region. However, the market acrossย Asia-Pacificย is expected to register the highest CAGR of 8.7% during the forecast period, owing to rapidly growing geriatric population, surge in public-private investment, and increase in number of initiatives for healthcare awareness.
For Purchase Inquiry-ย https://www.alliedmarketresearch.com/purchase-enquiry/60
Major market players
- Abbott Laboratories
- Baxter International Inc.
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
Request for 14 days free trial:ย https://www.alliedmarketresearch.com/avenue/trial/starter
โWe have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.โ
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.